These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34467996)

  • 41. Dysbetalipoproteinemia and other lipid abnormalities related to apo E.
    Cenarro A; Bea AM; Gracia-Rubio I; Civeira F
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():50-55. PubMed ID: 34006354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
    de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
    J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The spectrum of type III hyperlipoproteinemia.
    Sniderman AD; de Graaf J; Thanassoulis G; Tremblay AJ; Martin SS; Couture P
    J Clin Lipidol; 2018; 12(6):1383-1389. PubMed ID: 30318453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of very low density lipoproteins and intermediate density lipoproteins of normo- and hyperlipidemic apolipoprotein E-2 homozygotes.
    Schmitz G; Assmann G; Augustin J; Dirkes-Kersting A; Brennhaüsen B; Karoff C
    J Lipid Res; 1985 Mar; 26(3):316-26. PubMed ID: 3989390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dysbetalipoproteinaemia--clinical and pathophysiological features.
    Blom DJ; Byrnes P; Jones S; Marais AD
    S Afr Med J; 2002 Nov; 92(11):892-7. PubMed ID: 12506591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype.
    Shahmanesh M; Jaleel H; DeSilva Y; Ross JD; Caslake M; Cramb R
    Sex Transm Infect; 2001 Aug; 77(4):283-6. PubMed ID: 11463929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
    Feussner G; Funke H; Weng W; Assmann G; Lackner KJ; Ziegler R
    Eur J Clin Invest; 1992 Sep; 22(9):599-608. PubMed ID: 1360898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
    de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Familial dysbetalipoproteinemic subjects with the E3/E2 phenotype exhibit an E2 isoform with only one cysteine residue.
    Smit M; de Knijff P; Frants RR; Klasen EC; Havekes LM
    Clin Genet; 1987 Nov; 32(5):335-41. PubMed ID: 3690877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.
    Koopal C; Marais AD; Visseren FL
    Curr Opin Endocrinol Diabetes Obes; 2017 Apr; 24(2):133-139. PubMed ID: 28098593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
    Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
    Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homozygous familial hypercholesterolemia occurring with apoprotein E3 deficiency. Report of two cases.
    Nestel PJ; Reardon MF; Fidge NH
    Arteriosclerosis; 1984; 4(2):124-9. PubMed ID: 6704049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apolipoprotein E genotype modulates the effect of black tea drinking on blood lipids and blood coagulation factors: a pilot study.
    Loktionov A; Bingham SA; Vorster H; Jerling JC; Runswick SA; Cummings JH
    Br J Nutr; 1998 Feb; 79(2):133-9. PubMed ID: 9536857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Remnant disease associated with apoprotein E1; clinical importance of apoprotein E (apo E) phenotypes].
    Borghini I; James RW; Pometta D
    Schweiz Med Wochenschr; 1989 Dec; 119(50):1821-4. PubMed ID: 2609136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.
    de Knijff P; van den Maagdenberg AM; Stalenhoef AF; Leuven JA; Demacker PN; Kuyt LP; Frants RR; Havekes LM
    J Clin Invest; 1991 Aug; 88(2):643-55. PubMed ID: 1864973
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia.
    Mahley RW; Innerarity TL; Rall SC; Weisgraber KH
    Ann N Y Acad Sci; 1985; 454():209-21. PubMed ID: 3000263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance.
    Smit M; de Knijff P; van der Kooij-Meijs E; Groenendijk C; van den Maagdenberg AM; Gevers Leuven JA; Stalenhoef AF; Stuyt PM; Frants RR; Havekes LM
    J Lipid Res; 1990 Jan; 31(1):45-53. PubMed ID: 2313204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations.
    Carmena R; Roy M; Roederer G; Minnich A; Davignon J
    Atherosclerosis; 2000 Jan; 148(1):113-24. PubMed ID: 10580177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Familial apolipoprotein E deficiency.
    Schaefer EJ; Gregg RE; Ghiselli G; Forte TM; Ordovas JM; Zech LA; Brewer HB
    J Clin Invest; 1986 Nov; 78(5):1206-19. PubMed ID: 3771793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.